<DOC>
	<DOCNO>NCT00663052</DOCNO>
	<brief_summary>The purpose study compare safety efficacy different dos etanercept treatment moderate severe psoriasis .</brief_summary>
	<brief_title>Study Evaluating Etanercept Treatment Moderate Severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>18 year age old time consent . Active , moderate severe chronic plaque psoriasis define follow criterion : Clinically stable , plaque psoriasis involve great equal 10 % body surface area ( BSA ) PASI great equal 10 . In opinion investigator , failure , intolerance , contraindication candidate following : Methotrexate ( MTX ) , cyclosporine psoralen plus ultraviolet A radiation ( PUVA ) therapy . Evidence skin condition ( e.g. , eczema ) psoriasis would interfere evaluation effect study medication psoriasis . Rheumatologic disease rheumatoid arthritis , systemic lupus erythematous , systemic vasculitis , scleroderma polymyositis , associate syndrome . Active recent ( within 2 year ) tuberculosis ( TB ) infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Enbrel</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Topical Psoriasis</keyword>
	<keyword>Wyeth Psoriasis</keyword>
	<keyword>Active Psoriasis</keyword>
</DOC>